mAbs Against HUMAN Protein
CD19
| STATUS: | |
|---|---|
| CONTACT INFORMATION: | University of Oxford marketed by Ximbio.com |
| TYPE: | mouse anti human |
| CLONE NAME: | PDR134 |
| PROTEIN: | CD19 |
| PROTEIN WEB: | https://www.omim.org/entry/107265 |
| ANTIGEN USED: | Pokeweek-stimulated Daudi and Raji cells |
| FUSION PARTNER: | P3/NS1/1-Ag4.1 |
| ISOTYPE: | IgM |
| SPECIES REACTIVITY: | Human |
| PREPARATION AND STORAGE: | Aliquot and store at 4C. Do not freeze |
| COMMERCIALIZED BY: | Ximbio.com |
| APP RECOMMENDED: | FACS IHC IF IP WB |
Description
CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by progenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic lymphocytic leukemia and non-Hodgkin’s lymphoma). Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.
References
Tedder TF et al. 1995. B-cell antigens: section report. In Schlossman SF, et al (eds) Leucocyte Typing V, Vol 1, Oxford University Press, Oxford, New York and Tokyo, p 491.
Sato S and Tedder TF. 1997. CD19 Workshop Panel report. In Kishimoto T, et al (eds) Leucocyte Typing VI, Garland Publishing Inc., New York and London, p 133-135